FDA intends to take action against non-FDA-approved GLP-1 drugs

Source: Hacker News

For Immediate Release – February 6, 2026

Statement From: Martin A. Makary, M.D., M.P.H.
Commissioner of Food and Drugs – Food and Drug Administration

Today, the U.S. Food and Drug Administration is announcing its intent to take decisive steps to restrict GLP‑1 active pharmaceutical ingredients (APIs) intended for use in non‑FDA‑approved compounded drugs that are being mass‑marketed by companies—including Hims & Hers and other compounding pharmacies—as similar alternatives to FDA‑approved drugs. These actions are aimed at safeguarding consumers from drugs for which the FDA cannot verify quality, safety, or efficacy. We take seriously any potential violations of the Federal Food, Drug, and Cosmetic Act.

The FDA is also taking steps to combat misleading direct‑to‑consumer advertising and marketing following warning letters that were sent in the fall of 2025. In promotional materials, companies cannot claim that non‑FDA‑approved compounded products are generic versions or the same as drugs approved by the FDA. They also cannot state that compounded drugs use the same active ingredient as the FDA‑approved drugs or that compounded drugs are clinically proven to produce results for the patient.

The FDA will use all available compliance and enforcement tools within its authorities to address unsubstantiated claims and associated public health concerns. Entities engaged in the manufacture, distribution, or marketing of unapproved compounded GLP‑1 products should be aware that failure to adequately address any violations may result in legal action without further notice, including, without limitation, seizure and injunction.

Boilerplate

The FDA, an agency within the U.S. Department of Health and Human Services, protects public health by assuring the safety, effectiveness, and security of human and veterinary drugs, vaccines, and other biological products for human use, as well as medical devices. The agency is also responsible for the safety and security of the nation’s food supply, cosmetics, dietary supplements, radiation‑emitting electronic products, and for regulating tobacco products.